-
2025-523895-22-00
4
Non-small cell lung cancer (NSCLC)
-
2025-524646-94-00
11
Obstetrics – Preeclampsia
-
2025-524675-23-00
6
Ulcerative Colitis
-
2025-525013-23-00
4
Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
-
2025-523269-31-00
3
2026-06-02
Hormone receptor-positive early breast cancer in post-menopausal women
-
2025-522896-27-00
4
2026-05-11
Asthma
-
2025-522996-27-00
5
2026-05-05
recurrent and/or metastatic squamous cell carcinoma of the head and ne
-
2023-508047-40-00
5
2026-04-30
Ovarian cancer
-
2025-520466-22-00
5
2026-04-29
Advanced Platinum-resistant Epithelial Ovarian Cancer
-
2025-523742-27-00
9
2026-04-28
Advanced solid tumors
-
2024-519444-33-00
5
2026-03-12
HER2-expressing endometrial cancer (IHC 3+/2+)
-
2024-520027-88-00
4
2026-02-12
Patients with hormone receptor-positive (HR+) breast cancer
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2025-521514-26-00
5
2026-01-26
Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2023-505661-89-00
4
2025-12-19
Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
-
2025-521780-12-00
11
2025-12-16
Non-ischemic cardiomyopathy
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2024-514084-26-00
5
2025-08-22
Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphom
-
2024-518589-29-00
5
2025-08-21
Bronchiectasis
-
2024-519551-29-00
5
2025-08-21
Acute cerebral ischemic stroke
-
2024-512753-24-00
5
2025-08-05
Acute Myeloid Leukemia (AML)
-
2024-512360-55-00
4
2025-06-30
Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
-
2023-505172-29-00
4
2025-04-24
Resectable Non-small Cell Lung Cancer